0001209191-23-051982.txt : 20231004 0001209191-23-051982.hdr.sgml : 20231004 20231004163514 ACCESSION NUMBER: 0001209191-23-051982 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231002 FILED AS OF DATE: 20231004 DATE AS OF CHANGE: 20231004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Novack David F CENTRAL INDEX KEY: 0001573072 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34207 FILM NUMBER: 231308476 MAIL ADDRESS: STREET 1: 39 YORKSHIRE DR CITY: OAKLAND STATE: CA ZIP: 94618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DYNAVAX TECHNOLOGIES CORP CENTRAL INDEX KEY: 0001029142 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330728374 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 POWELL STREET STREET 2: SUITE 720 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5108485100 MAIL ADDRESS: STREET 1: 2100 POWELL STREET STREET 2: SUITE 720 CITY: EMERYVILLE STATE: CA ZIP: 94608 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-02 0 0001029142 DYNAVAX TECHNOLOGIES CORP DVAX 0001573072 Novack David F C/O DYNAVAX TECHNOLOGIES 2100 POWELL STREET, SUITE 720 EMERYVILLE CA 94608 0 1 0 0 President & COO 1 Common Stock 2023-10-02 4 M 0 40000 5.42 A 43187 D Common Stock 2023-10-02 4 S 0 20000 14.75 D 23187 D Common Stock 2023-10-02 4 S 0 20000 15.00 D 3187 D Stock Option (Right to Buy) 5.42 2023-10-02 4 M 0 40000 D 2027-02-11 Common Stock 40000 69000 D The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on May 5, 2023. This transaction was executed in multiple trades at prices ranging from $14.66 to $14.86; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 12, 2020, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter. Not applicable. /s/ David Novack 2023-10-04